Welcome to our dedicated page for Regen Biopharma news (Ticker: RGBPP), a resource for investors and traders seeking the latest updates and insights on Regen Biopharma stock.
Regen BioPharma PFD A (RGBPP) is a preferred share class of Regen BioPharma, Inc., a publicly traded biotechnology company on the OTC Pink marketplace. Company news for RGBPP reflects developments at Regen BioPharma in immunology, immunotherapy, and its lead cell‑based therapeutic program, HemaXellerate.
News releases highlight Regen BioPharma’s efforts to advance HemaXellerate, a stem cell‑derived therapy designed to stimulate bone marrow regeneration and restore healthy blood cell production. The company reports FDA Investigational New Drug clearance for HemaXellerate and has discussed plans and preparations for a Phase I clinical trial in aplastic anemia, a rare and serious bone marrow disorder.
Investors following RGBPP news can also see updates on Regen BioPharma’s regulatory interactions, including submission of an Orphan Drug Application for HemaXellerate in aplastic anemia and the company’s process of addressing FDA comments on that application. Additional news items describe the exploration of chemotherapy‑induced bone marrow suppression as a second indication, positioning HemaXellerate as a potential multi‑lineage regenerative approach in oncology supportive care.
Beyond HemaXellerate, Regen BioPharma news covers its broader pre‑clinical pipeline spanning cell therapies, RNA vaccines, RNA and DNA therapeutics, and small molecule drugs for cancer and autoimmune disorders. The company frequently uses Emerging Growth Conference presentations to discuss scientific progress, clinical plans, and programs such as DuraCAR, offering investors and analysts a forum to ask questions in real time.
For holders and prospective investors in RGBPP, this news feed provides a centralized view of Regen BioPharma’s scientific updates, clinical trial planning, orphan drug strategy, and capital markets communications related to its immunology and immunotherapy focus.
Regen BioPharma, Inc. (RGBP, RGBPP) is launching a development program for its modified mRNA anti-cancer vaccine targeting the Survivin protein. The initial phase includes pre-clinical studies essential for an FDA IND submission. This patented technology involves using modified mRNA to produce Survivin peptides that activate dendritic cells, aiming to combat cancer effectively. Survivin's role in inhibiting cell death makes it a critical target for cancer therapies. CEO David Koos expressed optimism about advancing this technology, especially with potential applications beyond pancreatic cancer.
Regen BioPharma (PINK: RGBP, RGBPP) has made significant strides under CEO David R. Koos since March 2021, overcoming financial and legal challenges. The company revived valuable intellectual property, settled a $1.2M lawsuit, and became current with SEC filings, safeguarding its public trading status. In Q3 2021, Regen generated $1.9M from licensing agreements, although revenue accounting will be adjusted per ASC 606. Looking ahead, Koos aims to secure more collaborations to advance clinical trials without drawing a salary, reflecting his commitment to the company’s future.
Regen BioPharma (PINK: RGBP, RGBPP) has announced a strategic shift towards in-vitro diagnostics, focusing on regenerative medicine. The company has entered a non-binding Letter of Intent to acquire Canary Oncoceutics, a firm developing precision oncology tests. This acquisition is contingent on due diligence and a crucial need for $50 million in funding to support development. Canary’s innovative technology aims to enhance cancer treatment by personalizing drug recommendations based on individual tumor responses. The global cancer diagnostics market is projected to grow from $168 billion in 2020 to $280 billion by 2028.